Skip to main content

iwCLL 2023 Main banner

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

S
1105
SAFETY AND EFFECTIVENESS IN CLL PATIENTS TREATED WITH VENETOCLAX MONOTHERAPY IN AUSTRIA, GERMANY, AND SWITZERLAND - LONG TERM FOLLOW UP DATA
Therapy of CLL

Favorite
1121
Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with chronic lymphocytic leukemia treated with continuous novel agents
Clinical Challenges in CLL

Favorite
1116
SAFETY PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA UNDERGOING TREATMENT WITH 1ST AND 2ND GENERATION BRUTON TYROSINE KINASE INHIBITORS: MULTICENTRIC REAL-WORLD EXPERIENCE
Therapy of CLL

Favorite
1163
Sensitive monitoring of sequential targeted therapy resistance in relapsed/therapy refractory chronic lymphocytic leukemia
Clinical Challenges in CLL

Favorite
3001
Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Clinical Challenges in CLL

Favorite
1136
Serum Monoclonal Immunoglobulin Predicts Inferior Prognosis in Patients Treated for Chronic Lymphocytic Leukemia
Past, Present, and Future in CLL

Favorite
1031
Sex Bias in Mutational Landscape of Chronic Lymphocytic Leukemia: Analysis of Clinical Sequencing Data
Pathogenesis of CLL

Favorite
1048
SH2-Flow: A Multiplex Single Cell Phosphotyrosine Profiling Tool for B-cell Malignancies
Pathogenesis of CLL

Favorite
1126
Significance of sIL-2R and LD in predicting time to first treatment in Japanese CLL patients with early asymptomatic disease.
Clinical Challenges in CLL

Favorite
1157
Significance of TP53 aberrations in context of other pathogenic sequence variants in patients with chronic lymphocytic leukemia in the era of targeted therapy
Clinical Challenges in CLL

Favorite
1118
Similar discriminatory values of IPS-E, AIPSE, and CR0 scores predicting time to first treatment in a large series of unselected patients with early-stage CLL
Past, Present, and Future in CLL

Favorite
1228
Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
Clinical Challenges in CLL

Favorite
1103
Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients
Clinical Challenges in CLL

Favorite
1120
Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.
Pathogenesis of CLL

Favorite
1033
Single-Cell Transcriptome Profiling Reveals Neoplastic Effects of Exosomal S100A4 in Chronic Lymphocytic Leukemia
Pathogenesis of CLL

Favorite
1055
Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Clinical Challenges in CLL

Favorite
1128
Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia
Past, Present, and Future in CLL

Favorite
4005
STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Therapy of CLL

Favorite
1153
SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Therapy of CLL

Favorite
1110
Systematic literature review (SLR) of treatments and outcomes in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitors (BTKi) and venetoclax
Clinical Challenges in CLL

Favorite